ITOC (iTonic Holdings) Ending Cash Position: $1.49 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ITOC iTonic Holdings Ltd ITOC
14 GF Score
Price $0.31
! 6 Warning Signs
View Full Analysis

What is iTonic Holdings Ending Cash Position?

iTonic Holdings ITOC +6.24% 14 Ending Cash Position is $1.49 Mil as of Dec. 2025. GuruFocus rates ITOC with a GF Score™ of 14/100. The stock has 6 warning signs investors should review.

iTonic Holdings's Ending Cash Position for the quarter that ended in Dec. 2025 was $1.49 Mil.

iTonic Holdings's quarterly Ending Cash Position declined from Dec. 2024 ($6.16 Mil) to Jun. 2025 ($1.81 Mil) and declined from Jun. 2025 ($1.81 Mil) to Dec. 2025 ($1.49 Mil).

iTonic Holdings's annual Ending Cash Position increased from Dec. 2023 ($0.23 Mil) to Dec. 2024 ($6.16 Mil) but then declined from Dec. 2024 ($6.16 Mil) to Dec. 2025 ($1.49 Mil).

iTonic Holdings Ending Cash Position Related Terms

iTonic Holdings Ending Cash Position Historical Data

* Premium members only.

The historical data trend for iTonic Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iTonic Holdings Ending Cash Position Chart

iTonic Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.14 0.07 0.23 6.16 1.49

iTonic Holdings Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.03 6.16 1.81 1.49
ITOC
14GF Score
iTonic Holdings Ltd ITOC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iTonic Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

iTonic Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.159+-4.669
=1.49

iTonic Holdings's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.809+-0.319
=1.49

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.49 Mil mean?
iTonic Holdings (ITOC) has a Ending Cash Position of $1.49 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on iTonic Holdings and its competitors.
Is iTonic Holdings' Ending Cash Position too high?
iTonic Holdings' current Ending Cash Position is $1.49 Mil. Overall, iTonic Holdings has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does iTonic Holdings' Ending Cash Position compare to USAQ and ALURD?
iTonic Holdings' Ending Cash Position of $1.49 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on iTonic Holdings and its competitors. iTonic Holdings's current Ending Cash Position is $1.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iTonic Holdings stock overvalued right now?
iTonic Holdings (ITOC) has a current Ending Cash Position of $1.49 Mil. The current Ending Cash Position is $1.49 Mil. iTonic Holdings' overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For iTonic Holdings (ITOC), the current Ending Cash Position is $1.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

iTonic Holdings Business Description

Address No. 8 Beiyuan Xiaojie, Room 405, LongHu Hailanyinqing Industrial Park, Building 6, Chaoyang District, Beijing, CHN
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.
14GF Score

Get the complete analysis for ITOC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price